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a b s t r a c t
Background: Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades
of active development of AML therapeutics. Currently, the 5-year survival of AML patients is about 30% and for
elderly patients, the rate drops to b10%. About 30% of AML patients harbor an activating mutation in the tyrosine
kinase domain (TKD) of Fms-Like Tyrosine kinase 3 (FLT3) or a FLT3 internal tandem duplication (FLT3-ITD). Inhibitors of FLT3, such as Rydapt that was recently approved by the FDA, have shown good initial response but patients often relapse due to secondary mutations in the FLT3 TKD, like D835Y and F691 L mutations.
Methods: Alkynyl aminoisoquinoline and naphthyridine compounds were synthesized via Sonogashira coupling.
The compounds were evaluated for their in vitro and in vivo effects on leukemia growth.
Findings: The compounds inhibited FLT3 kinase activity at low nanomolar concentrations. The lead compound,
HSN431, also inhibited Src kinase activity. The compounds potently inhibited the viability of MV4–11 and
MOLM-14 AML cells with IC50 values b1 nM. Furthermore, the viability of drug-resistant AML cells harboring
the D835Y and F691 L mutations were potently inhibited. In vivo efﬁcacy studies in mice demonstrated that
the compounds could drastically reduce AML proliferation in mice.
Interpretation: Compounds that inhibit FLT3 and downstream targets like Src (for example HSN431) are good
leads for development as anti-AML agents.
Fund: Purdue University, Purdue Institute for Drug Discovery (PIDD), Purdue University Center for Cancer Research, Elks Foundation and NIH P30 CA023168.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).

1. Introduction
Acute myeloid leukemia (AML) is a devastating disease, which still
remains difﬁcult to treat despite massive efforts by drug companies
and academia to ﬁnd durable cures [1]. The ﬁve-year survival rate for
AML hovers around 30% and for elderly patients over 65 years, the
ﬁve-year survival rate is unfortunately low (b10%) [2–4]. It is hoped
that the survival rate for AML will soon improve due to the introduction
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of newer and more potent FLT3 inhibitors and advances made in allogeneic bone marrow transplantation. AML is a heterogenous disorder with
an array of mutations that contribute differentially to prognosis [5].
About 30% of AML patients harbor a mutation in the Fms-Like Tyrosine
Kinase 3 (FLT3), which makes the leukemia more aggressive [6,7]. Internal tandem duplication (ITD) in the juxtamembrane domain as well as
tyrosine kinase domain (TKD) mutations, like those at residues D835
and F691, constitute FLT3 activating mutations [8–10]. When these mutations are present, FLT3 signaling bypasses the requirement of the FLT3
ligand for activation and hence becomes constitutively activated.
Midostaurin (Rydapt), a FLT3 tyrosine kinase inhibitor (TKI), was
approved in 2017 [11,12] and other FLT3 TKIs are being evaluated in
clinical trials [13]. Midostaurin is not effective as a single agent and it
is administered in combination with chemotherapy [11,12]. The

https://doi.org/10.1016/j.ebiom.2019.01.012
2352-3964/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Research in context
Evidence before this study
FLT3 is a druggable target for about 30% of AML patients who
harbor mutated FLT3 (ITD or TKD). A handful of FLT3 inhibitors
evaluated in the clinic show good initial treatment response but
patients ultimately relapse due to secondary mutations such as
D835Y and F691 L, and other oncogenic activations. Hence therapeutic agents capable of inhibiting drug-resistantAML are
desirable.
Added value of this study
In this study, we presented alkynyl aminoisoquinoline and
naphthyridine compounds as novel inhibitors of FLT3 kinase activity as well as downstream kinases such as Src/Raf. Importantly,
the compounds potently inhibited the growth of drugresistantAML harboring the commonly observed D835Y and
F691 L secondary mutations. The reported compounds are also
efficacious in vivo (human AML xenograft models).
Implications of all the available evidence
This study provides new chemical entities that could be translated
into therapeutics for relapsed AML patients who fail first/s generation FLT3 inhibitors, which are not very active against AML cells
harboring D835 or F691 mutations.

Bioscience (Irvine, CA, USA). MV4–11 cell line was a kind gift from Dr.
Mark Levis (Johns Hopkins University). MOLM-14 (FLT3-ITD, D835Y)
and MOLM-14 (FLT3-ITD, F691 L) [25] were kind gifts from Dr. Neil
Shah (UCSF). The cells were routinely maintained in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum at 37 °C with 5% CO2.
2.2. Analysis of antiproliferative activities
Cells were seeded into 96-well tissue culture-treated plates at 2.0
× 104 cells/mL for up to 24 h. DMSO stock solutions of compounds
were serially diluted ﬁrst in DMSO and subsequently into RPMI before
being added to the cell cultures in triplicates, with 10 μM being the
highest tested concentration. The plates were incubated for 72 h as
above. The CellTitre-Blue assay (Promega, Madison WI) was then
added to the cultures and incubated a further 4 h before the ﬂuorescence measured following the manufacturers recommendations. The
ﬂuorescence data from compounds were normalized to that DMSO
and the resulting data ﬁtted to a non-linear regression equation to obtain IC50 using GraphPad Prism 5.0 Software (La Jolla, CA, USA).
To determine the effect of HSN431 on actual leukemia cell counts,
MV4–11 cells were seeded into 96 well plates as above and treated
with either DMSO vehicle, or HSN431 at the following concentrations:
0.1 nM, 0.2 nM, 0.5 nM, 1 nM, 2 nM, 5 nM, and 10 nM. Cells were incubated for 72 h, and then counted using trypan blue exclusion on the
Countess automated cell counter (Life Technologies, Carlsbad, CA). Cell
counts were performed in triplicates, and the averages, standard deviations and t-test statistical analyses were graphed using GraphPad Prism
software (GraphPad, La Jolla, CA).
2.3. In vitro kinase assay

majority of the FLT3 inhibitors, which have been or are being evaluated
in clinical trials show initial response, but patients often relapse with
various FLT3 mutations (including secondary FLT3 mutations) and
complete remission of AML is challenging [8,9,14–17]. FLT3 D835Y/V
[18] and F691 L [17] are common mutations, which often emerge during
treatment and are resistant to many FLT3 TKIs. New-generation FLT3 inhibitors that could be used as a mono therapy and/or exhibiting potencies against mutated FLT3 (such as D835Y/V or F691 L) could improve
AML survival rates.
Several kinases, which are downstream of FLT3, collaborate with
constitutively active FLT3 (FLT3-ITD or FLT3 with mutation in the kinase
domain, particularly the D835 or F691 mutations), to exacerbate AML
[19–22]. Src-family kinases play pivotal roles in microenvironmentinduced resistance to FLT3 inhibition [23]. Therefore, dual inhibitors of
FLT3-Src-family kinases could be effective in overcoming drug resistance. We recently reported that novel dual FLT3-Src-family kinase inhibitors (see Fig. 1) that contain alkynyl aminoisoquinoline moiety
potently inhibited FLT3-ITD harboring AML cell lines, such as MV4–11
and MOLM-14, with single digit nanomolar or even sub-nanomolar
half maximal inhibitory concentration (IC50) values in vitro [24]. The
impressive in vitro efﬁcacies of the alkynyl aminoisoquinoline and
alkynyl aminonaphthyridine compounds against AML cell lines harboring FLT3-ITD prompted us to conduct an extensive structure-activity relationship (SAR) studies and to evaluate the efﬁcacy of these
compounds in mice. Here we present the SAR and corresponding efﬁcacies of the second-generation alkynyl aminoisoquinoline and alkynyl
aminonaphthyridine compounds.
2. Materials and methods
2.1. Chemicals, reagents and cell culture
Midostaurin was purchased from Sigma (St. Louis, MO, USA),
crenolanib, quizartinib and ponatinib were purchased from Adooq

Cell-free kinase activity assays were performed at Reaction Biology
Corporation. Brieﬂy, kinases were incubated with substrates, 100 μM
ATP and a 3-fold serial dilution of compounds starting at 1 μM. DMSO
was used as control. For single-dose inhibition of FLT3-ITD and Src kinase activity, compounds were tested at 500 nM. Experiments were
performed in duplicates. The concentrations of kinases and substrates
used in the assays are indicated on Table S1. Kinase activity was quantiﬁed using the ADP-Glo™ Kinase Assay System (Promega, Madison, WI)
following the manufacturer's recommendations.
2.4. In vivo efﬁcacy studies
The in vivo efﬁcacy of compounds was assessed in an orthotopic
human AML model in NSG (NOD scid gamma, NOD-scid IL2Rgnull)
mice that were bred at University of Maryland Baltimore (mating
pairs acquired from Jackson Laboratories; Maine). Female NSG or NRG
(NOD-Rag1null IL2rgnull, NOD rag gammaRnull, bred at Purdue University) mice (6–8 weeks old) were injected with 1 × 106 MV4–11-luc
cells, a gift from Dr. Sharyn Baker (Ohio State University) via intravenous injection into the lateral tail vein of restrained mice. Three days
later, engraftment was assessed by imaging on a Xenogen IVIS-2 Imaging System (Alameda) after an intraperitoneal (IP) injection of
150 mg/kg luciferin. Mice were sorted into four or ﬁve groups (n = 5)
so that mean intensity (i.e., disease burden) was equal. Dosing started
on day of sorting. Compounds were dissolved in 85% PBS (pH 7.4) buffer
containing 10% DMSO and 5% Cremophore. The vehicle (buffer without
compounds) was used as control. Mice were injected 3 to 5 days per
week via IP injection. Mice were weighed on day of dosing and imaged
once per week. The endpoint of each study was survival (mice were euthanized via AVMA-approved methods when they lost N20% of body
weight or displayed hind limb paralysis). All mice were housed in a
12-h light/dark cycle with access to food and water ad libitum. Studies
were performed with Institutional Animal Care and Use Committee
(UMB and Purdue University) approval.
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Fig. 1. Dual FLT3/Src-kinase inhibitors reported by Larocque et al. [24].

2.5. Western blot analysis

2.7. Statistical analysis

MV4–11 cultures were treated with 2 nM and 10 nM of compounds for 6 h and 48 h. Total protein extraction, gel separation,
transfer and imaging of blots were performed as previously described [26]. The following primary antibodies from Cell Signaling
Technologies (MA, USA) were used: Phospho-p70S6K (cat. no.
9205, RRID: AB_330944), p70S6K (cat. no. 9202, RRID: AB_331676),
Phospho-p38 (cat. no. 9211, RRID: AB_331641), p38 (cat. no. 9212,
RRID: AB_330713), c-Myc (cat. no. 9402, RRID: AB_2151827),
Phospho-FLT3 (cat. no. 3461, RRID: AB_331060), FLT3 (cat. no.
3462, RRID: AB_10693420), Phospho-STAT5 (cat. no. 9359, RRID:
AB_823649), STAT5 (cat. no. 9363, RRID: AB_2196923), PhosphoERK (cat. no. 9101, RRID: AB_331646), ERK (cat. no. 4695, RRID:
AB_390779), Phospho-AKT (cat. no. 9271), AKT (cat. no. 9272,
RRID: AB_329825), Phospho-Src (cat. no. 2101, RRID: AB_331697),
Src (cat. no. 2110, RRID: AB_2106058), Phospho-STAT3 (cat. no.
9145, RRID: AB_2491009), STAT3 (cat. no. 12640, RRID: AB_
2629499). Mouse anti-β-Actin antibody was purchased from Sigma
(MO, USA). A horseradish peroxidase-conjugated anti-rabbit or
anti-mouse antibody (Cell Signaling Technologies) was used as secondary antibody. Scanned images were analyzed using image J
software.

Non-linear regression analysis of the cell-free in vitro kinase activity
dose-response data were performed using GraphPad Prism 5.0 Software
(GraphPad, La Jolla, CA, USA). Photon intensity on whole body and animal survival data were analyzed by students t-test (paired; two tailed)
in GraphPad Prism 5.0 Software (CA, USA). Signiﬁcant differences have
been indicated as * (P ≤ .05), ** (P ≤ .01) or *** (P ≤ .001) according to the
level of signiﬁcance.

2.6. Cell cycle analysis and apoptosis
Cells seeded into T-25 ﬂasks at a density of 8.0 × 104 cells/mL and incubated overnight at 37 °C with 5% CO2. Each treatment was performed
in triplicates, with three ﬂasks per treatment each with enough volume
for both assays at the applicable time points. Following the overnight incubation, cells were treated with either DMSO or different concentrations of HSN431 (as indicated) in triplicates, mixed well and
incubated. At each time point (24 and 48 h), aliquots of 1.5 mL of cells
were collected from each ﬂask and placed into labeled FACS tubes (for
Annexin V apoptosis) or labeled 15 cc conical tubes (for cell cycle) and
centrifuged at 300 × g for 5 min. Cells were washed twice with 1× PBS.
For cell cycle, cell pellets were resuspended in 0.5 mL PBS in 15 cc
conical tubes and ﬁxed with 4.5 mL of 70% ethanol. Fixed cells were
stored at −20 °C until analysis with the Propidium Iodide (PI) Flow Cytometry Kit (cat. no. ab139418, Abcam, Cambridge, MA, USA). Samples
were analyzed in duplicates on a FACSCanto II ﬂow cytometer (BD Bioscience, San Jose, CA, USA) and cell cycle distribution was analyzed
using the Watson algorithm analysis in FlowJo software (Flowjo, LLC,
Ashland, OR).
For Annexin V apoptosis, cell pellets were resuspended in 100 μL of
1× assay buffer and the binding of Annexin V and PI were measured
by staining cells following the BD Pharmingen™ FITC Annexin V Apoptosis Detection Kit I (cat. no. 556547, BD Biosciences, San Jose, CA,
USA) recommendations. Flow cytometry was performed on a a
FACSCanto II ﬂow cytometer (BD Bioscience, San Jose, CA, USA) and
data analyzed using the FlowJo software (Flowjo, LLC, Ashland, OR).

3. Results
3.1. Second generation compounds inhibit FLT3/Src kinase activity
For the expanded SAR study, additional nitrogens were incorporated
into rings A and B (see Fig. 2) of the ﬁrst-generation compounds
HSN286, HSN334 and HSN356 to improve aqueous solubility (lower
LogP). In addition to the water-solubilizing effects of basic nitrogens, it
has also been well documented that the introduction of the so-called
“essential nitrogen” or nitrile moieties into drugs improves target engagement [27,28]. Fluorine has also been deemed a “magic” moiety
that when incorporated into drugs could improve the potency as well
as stability of the drugs [29]. Therefore, analogs which also contained
ﬂuorine were synthesized (compounds 6, 7 and 17; Fig. 2).
The synthesis of the second-generation FLT3-Src inhibitors (Fig. 2)
were accomplished following a Sonogashira protocol previously reported by us, see SI [24]. With the compounds in hand, we evaluated
their inhibitory activities against FLT3 and Src kinases at 500 nM concentrations using the Reaction Biology company kinase screening
service (SI, Table S2). Compounds containing either monocyclic
(aminopyridines) or bicyclic (amino isoquinoline or naphthyridine)
moieties (in Fig. 2) potently inhibited (N90% inhibition of enzymatic
activity at 500 nM) FLT3 and Src kinases. When the benzamide moiety
in HSN286 (compound 8), HSN334 (compound 15) or HSN356 (Compound 19) was replaced with a nicotinamide to give compounds 9, 16
and 20, a signiﬁcant increase (~1 log unit) in predicted aqueous solubility was achieved (compare cLogP of compound 8 (5.7) with compound 9 (4.4); compound 15 (4.9) with compound 16 (3.6) and
compound 19 (4.0) with compound 20 (2.7)). The replacement of
the benzamide moiety in HSN286 with a nicotinamide moiety
(9) did not affect FLT3 or Src inhibition. Compound 9 inhibited the
proliferation of FLT3-ITD-harboring MV4–11 cells with a similar potency to HSN286 (both compounds inhibited MV4–11 cells with
IC50 value of ~0.5 nM). However, the replacement of the benzamide
moiety in HSN286 with picolinamide moieties (HSN286 to 10 or 11),
drastically affected the inhibition of FLT3 enzymatic activity (at
500 nM, HSN286 inhibited FLT3 enzymatic activity by 97% whereas
the picolinamide analogs, compounds 10 and 11 inhibited FLT3 at
75% and 43% respectively, see Table S2). Therefore, we opted to
make the nicotinamide derivatives HSN461 (compound 16), HSN459
(compound 20), compounds 5, 7, 13, 14, 18, 21 and 24.
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Fig. 2. Alkynyl aminoisoquinoline and alkynyl naphthyridine compounds and other FLT3 inhibitors (midostaurin, quizartinib, crenolanib and ponatinib) evaluated in this study.

To further probe the kinase inhibitory activity, we proceeded to determine the IC50 values of the compounds against FLT3-ITD and Src.
Since almost all the compounds had excellent FLT3 and Src inhibition
(Table S2), we chose representative compounds for isoquinolines
(HSN431) and naphthyridines (HSN459). HSN431 was equipotent
against both kinases (12.5 nM against FLT3-ITD and 12.6 nM against
Src kinase). HSN459 had an IC50 of 4.8 nM against FLT3-ITD and
12.2 nM against Src (Fig. 3).

newer generation FLT3 inhibitors, such as crenolanib, which are type I inhibitors fare better in binding to FLT3-ITD (F691 or D835) secondary mutated kinases but as already mentioned midostaurin is not active as a single
agent [11,12] and crenolanib suffers from pharmacokinetic issues [33] and
requires multiple dosing regimens. The need for novel FLT3-targeted AML
therapeutics that are active against the problematic secondary mutations
can therefore not be overstated. Pleasingly, a handful of the compounds
that showed excellent activities against FLT3-ITD-harboring MV4–11
cells, also showed very good activity (using the MTT assay) against the
drug-resistant MOLM-14 cell lines that harbored F691 L and D835Y secondary mutations. To conﬁrm that the compounds were killing the AML
cell lines, rather than just inhibiting growth, we used trypan blue exclusion
assay to count viable cells after incubating MV4–11 with one model compound, HSN431. The cell count indicated that viable MV4–11 cells decreased in presence of compound in dose-dependent manner (Fig. S1).

4. Compounds inhibit AML cells harboring FLT3 TKD mutations
Having established that the second-generation compounds were potent inhibitors of MV4–11 cell proliferation (most compounds inhibited
MV4–11 cells with IC50 b10 nM), we proceeded to evaluate the activities
of the compounds against drug-resistant AML cell lines. As previously
stated, the majority of FLT3 inhibitors provide initial response in the clinic
but none provide complete cure due to the emergence of resistance mechanisms. One of the major resistance mechanisms to FLT3 inhibitors is the
emergence of a secondary mutation in the kinase domain [30,31]. Patients
with double FLT3-ITD secondary TKD mutations have poorer prognosis
than those with single FLT3-ITD or FLT3 TKD mutations. For example sorafenib, an FDA-approved drug for thyroid, liver and kidney cancers, potently
binds to FLT3 and FLT3-ITD with Kd values of 13 nM and 95 nM respectively and has shown activity against AML in the clinic [32]. But sorafenib
is a poor binder of FLT3-ITD (D835V) or FLT3-ITD (F691 L) with Kd values
of 630 nM and 860 nM respectively and resistance to sorafenib due to secondary mutations in FLT3 has been documented [18]. Midostaurin and

a

4.1. Active compounds possess in vivo efﬁcacy against MV4–11 cells
Compounds HSN431, HSN459, 7, 11, 15, 20 and 26, inhibited MOLM14 (FLT3-ITD, D835Y) and MOLM-14 (FLT3-ITD, F691 L) with IC50
values that are 15 nM or lower (see Fig. 4 and Table 1). HSN459,
HSN431 as well as compounds 5, 9, 13, 18 and 24, were impressive as
they were more active against MV4–11 cells and drug-resistant
MOLM-14 cell lines than even the FDA-approved FLT3 inhibitor,
midostaurin, or most FLT3 compounds in clinical trials (crenolanib,
quizartinib and ponatinib, see Fig. 4 and Table 1). The ultimate goal of
this study was to identify a preclinical compound that could be
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Fig. 3. In vitro kinase inhibition activity of select compounds. Inhibition of (a) FLT3-ITD (100 nM) and (b) Src (0.6 nM) by HSN431 and HSN459. IC50 values of each compound are shown in
parenthesis. ATP concentration was 100 μM. Substrates used and substrate concentrations are presented in Table S1. Each data point represents the mean ± SD of duplicate measurements.
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translated into an AML therapeutic, so we proceeded to evaluate the
compounds against MV4–11 cells in mice (Figs. 5–7 and S2–S5).
The compounds that displayed potent activities against the AML cell
lines in vitro (HSN286, HSN334, HSN352, HSN356, HSN431, HSN459,
HSN461, HSN580, HSN581 and HSN620) were advanced for in vivo tolerability and efﬁcacy studies on six-week-old NSG or NRG mice (see
Figs. 5 & S2–S5). Female mice were dosed daily for 5 days via intraperitoneal injection and then monitored for an additional week for weight
loss, a sign of toxicity in mice. It was found that when administered intraperitoneally, most of the compounds were tolerated at 25 mg/kg (no
or transient weight loss b20% body weight). To evaluate the antileukemic efﬁcacy in vivo, six-week-old female NSG or NRG mice were
injected intravenously with FLT3-ITD expressing acute myeloid leukemia cells (MV4–11), expressing luciferase. Ten days after the initial
MV4–11 injection, most of the mice showed some leukemia burden.
Dosing (i.p) with the compounds was then started. The mice were
dosed with 25 mg/kg of the compounds three times a week (MWF).
Apart from HSN286, most of the tested compounds showed N99% reduction in leukemia burden after a few weeks (see Figs. 5 & S2–S5).
HSN431, HSN580 and HSN459 were notable and it appeared that
these compounds had cleared N99% of the leukemia in mice after few
days. At 25 mg/Kg, the mice in the HSN459 group lost weight after
one week so the dosing for this group was reduced to 10 mg/kg,
which was tolerable (see Fig. S5).
Since HSN431 could be dosed for several weeks without any adverse
events and all ﬁve mice were still alive after day 73 (see Fig. 5; all the
control mice had died by day 43), HSN431 was chosen as a model lead
candidate and characterized further (Western analysis, cell cycle and
apoptosis analysis).
In the wildtype FLT3 signaling, activation of FLT3 occurs through binding to FLT3 ligand and subsequent phosphorylation of its TKD [34]. This
causes the phosphorylation and activation of several downstream effector
proteins via signaling pathways like the phosphatidylinositol-3-kinase
(PI3K) - protein kinase B (Akt) and mitogen-activated protein kinase
(MAPK) pathways [34]. These signaling pathways interact with each
other and ultimately result in cell proliferation and survival [34]. Constitutive activation of FLT3 through mutations leads to constitutively active
downstream effectors and as such affords an enhanced cell survival and
proliferation. We used Western blot analysis to investigate the effect of
HSN431 on the phosphorylation of FLT3 and downstream effectors in
FLT3-ITD expressing MV4–11 cells (Figs. 6 & S6). In agreement with our
in vitro kinase results (Fig. 3 & Table S2), we observed an inhibition of
the phosphorylation of FLT3 (Fig. 6). Inhibition of FLT3 phosphorylation
was also observed in MOLM-14 (ITD, D835Y) cells (Fig. S7). In MV4–11
cells, inhibition of the phosphorylation of Src was also observed
(Fig. S8). Intriguingly, we found that after 48 h, the effect of HSN431 on
Src phosphorylation was lower at 10 nM compared to 2 nM compound
(Fig. S8). Although this was reproducible, the molecular basis is unclear
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and will be elucidated in future publications. We however, postulate
that at higher concentrations, the compound could affect other pathways
that modulate Src phosphorylation. Constitutive activation of Signal
Transducer and Activator of Transcription 3 and 5 (STAT3 and STAT5)
have been observed as a result of Src and FLT3 activation respectively
[35,36]. Consistent with the inhibition of Src and FLT3 phosphorylation,
STAT3 and STAT5 phosphorylation were inhibited (Figs. 6, S6 & S8).
From the Western blot analysis, we also observed decreased phosphorylation of both Akt and ribosomal protein S6 kinase beta-1 (p70S6K)
(Fig. S8), kinases in the PI3K-Akt-mTOR pathway that is activated in
FLT3 signaling [34]. Phosphorylation and activation of Akt leads to the activation of mammalian target of rapamycin (mTOR) which in turn activates p70S6K via phosphorylation [34]. Consequently, inhibition of Akt
phosphorylation would lead to decreased phosphorylation of p70S6K as
observed (Fig. S8). The activation of p70S6K leads to increased protein
translation, which is important for cell survival [34,37,38]. Interestingly,
from cell-free in vitro kinase assays, we found that HSN431 inhibited the
kinase activity of p70S6K with an IC50 of 44.7 nM but not the upstream
kinases PI3K, Akt and mTOR (Fig. 7). Hence inhibition of FLT3 kinase activity (Fig. 3) may be responsible for the observed decrease in Akt and
p70S6K phosphorylation.
The mitogen-activated protein kinase (MAPK) pathway has been
demonstrated to be involved in leukemogenesis due to the activation
of the Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) cascade [39]. Down-regulation of this cascade results in cell cycle arrest
and induces apoptosis [40,41]. Others have shown that the phosphorylation of p38 MAPK was enhanced in MV4–11 cells and p38 activity
has been implicated in leukemogenesis [42,43]. We observed inhibition of the phosphorylation of ERK, p38 and a modest inhibition of
c-Myc which is downstream of p38 by HSN431 (Fig. S8). For inhibition
of ERK phosphorylation, we found that HSN431 appeared to inhibit
ERK phosphorylation better after 6 h than after 48 h (Fig. S8). Timedependent increase in ERK phosphorylation following initial decrease
has been observed by others in MV4–11 and MOLM-14 cell lines
[44]. Further analysis by kinase inhibition assays revealed that
HSN431 inhibited the kinase activity of A-Raf (IC50 = 27.6 nM), BRaf (IC50 = 26.3 nM) and Raf-1 or c-Raf (IC50 = 12.8 nM) but not
the downstream effectors MEK1, ERK1 and RSK1 (Fig. 7). The observation that HSN431 inhibits the Raf kinase activity, which is required for
the activation of ERK, potentially explains the observed decrease in
cellular ERK phosphorylation.
4.2. HSN431 induces G1 cell cycle arrest and apoptosis
The effect of HSN431 on cell cycle in the AML cell lines was evaluated.
From the cell cycle analysis, an increase in the population of cells in the
G0/G1 phase was observed when the AML cell lines tested were treated
with HSN431. The accumulation of G0/G1 phase cells was observed to be
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Fig. 4. Anti-proliferative activity of second-generation compounds. The IC50 values against MV4–11 (black), MOLM-14 (red), MOLM-14 (ITD, D835Y) (blue) and MOLM-14 (ITD, F691 L)
(green) cells were plotted for each compound. Compounds with 15 nM or less IC50 against all 4 cell lines are marked with *. Each bar represents the average of triplicates plotted using
GraphPad Prism software (GraphPad, La Jolla, CA).
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Table 1
Summary of anti-proliferative activities of select compounds.
IC50 (mean ±SD, nM)

Compounds

5 (HSN580)
7 (HSN431)
9
13
18
20 (HSN459)
24
Midostaurin
Quizartinib
Crenolanib
Ponatinib

MV4–11

MOLM-14

MOLM-14 (ITD, D835Y)

MOLM-14 (ITD, F691 L)

0.4±0.004
0.5±0.01
0.4±0.04
0.4±0.006
0.2±0.001
0.3±0.004
0.2±0.009
18.5±2.4
0.4±0.02
3.1±0.06
0.1±0.001

2.8±0.02
0.5± 0.01
2.3± 0.1
1.4± 0.03
0.2±0.002
0.2±0.002
0.2± 0.01
16.1±0.02
0.5±0.02
4.5±0.8
0.5± 0.1

13.0±0.4
16.6±5.8
10.4±0.3
4.7±0.03
11.1±0.08
4.0±0.02
3.0±0.3
19.6±0.3
23.0±0.5
6.6±0.03
52.6±0.3

1.5±0.1
3.3±0.3
6.9±0.05
1.1±0.04
1.1±0.04
0.9±0.004
1.8±0.08
30.7±0.7
48.5±0.6
15.6±0.4
6.8±0.03

both dose- and time-dependent. Also, corresponding decreases in the
distribution of cells in the S phase (Figs. 8 and S9) were observed. A general decrease in the distribution of cells in the G2 phase was also observed. Additionally, we also observed an accumulation of cells in the
sub-G1 phase across the tested AML cell lines. A further analysis of the
antileukemic effect of HSN431 revealed that the compound induced apoptosis in the AML cell lines. Again, we observed both dose- and timedependent increases in total apoptosis (Figs. 9 and S10).

of AML patients [6,7], Src-family kinases, which are downstream of
FLT3, are over-expressed in AML and collaborate with FLT3 to facilitate
AML progression [46]. In addition to Src, HCK and Lyn (both are Src kinase family members) are inhibited by the reported aminoisoquinolines
[24]. HCK is known to be expressed in human primary leukemic stem
cells and not as much in human normal hematopoietic stem cells. Lyn
is known to play a key role in the progression of AML [47]. Indeed
dasatinib, a Src-family inhibitor, which is an FDA approved drug for
CML has been shown to be effective against AML [46]. We had earlier
reported that aminoisoquinoline benzamides are dual FLT3-Src-family
kinase inhibitors with potent activities against FLT3-ITD harboring
AML cell lines MV4–11 and MOLM-14 [24]. The ﬁrst-generation compounds (such as HSN286, HSN334 and HSN356) (Fig. 1) were however
not drug-like (high LogP values for example) and were poorly active

5. Discussion
Several reports have documented that the inhibition of FLT3 [1,45]
or Src kinase [46] is an attractive strategy to inhibit the proliferation of
AML. Whereas FLT3 plays a key role in leukemogenesis in about 30%
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against AML with secondary FLT3 mutations. However, the secondgeneration alkynyl aminoisoquinoline and alkynyl aminonaphthyridine
compounds (Fig. 2) had reduced LogP values and possessed potent activity against AML cell lines harboring secondary FLT3 mutations
(Fig. 4).
AML patients who harbor FLT3-ITD mutations have worst prognosis
[48]. Most FLT3 TKIs in clinical trials including crenolanib, quizartinib
and gilteritinib as well as midostaurin, the ﬁrst FDA approved FLT3
TKI, are effective against FLT3-ITD mutations [11,33,49,50]. It has
emerged that, the activation loop mutation D835Y/V as well as the gatekeeper mutation F691 L contribute signiﬁcantly to resistance to FLT3
TKIs, consequently leading to AML relapse [18,25,51]. The ability of a
FLT3 TKI to inhibit these mutant forms could translate into better clinical outcomes. HSN431, HSN459, and compound 24 among others, exhibited similar or better anti-leukemic activity against drug-resistant
AML cells including MOLM-14 cells harboring double FLT3-ITD-D835Y
and FLT3-ITD-F691 L mutations compared to midostaurin, crenolanib,
quizartinib and ponatinib.
In an in vivo mouse xenograft model, using MV4–11 model that was
previously used to evaluate crenolanib [33], HSN431 at 25 mg/kg and
dosed three times per week drastically reduced the whole-body photon
count due to the bioluminescence of MV4–11-luc cells, compared to
control. Furthermore, HSN431 treatment improved mice survival. By
day 40, all the control mice had died whereas 100% of HSN431-treated
mice were still alive (Fig. 5).
HSN431 is a multitargeted kinase inhibitor and it is likely that the
potent activity in vivo against AML is due to the ability to not only inhibit
FLT3 but some of the downstream targets. In fact, most kinase inhibitors,
including even ones that the investigators claimed were selective
agents, have now been shown to target multiple targets [52]. Plausibly

a

the clinical successes of the many FDA-approved TKIs, which are
multitargeting kinase inhibitors, derive from their ability to inhibit the
signaling pathway that lead to tumor/cancer growth (i.e. cancer driver
kinase and downstream “collaborating” kinases) as well as kinases
that regulate the tumor microenvironment [53] and/or immunokinases,
which either activate cytotoxic T-cells and/or inhibit suppressor immune cells [54]. A limitation of multitargeting kinase inhibitors is the
issue of dose-limiting toxicities, due to the inhibition of kinases that
are also essential for normal physiological function. Irrespective of
mode(s) of action, increasing survival of patients whiles not drastically
impacting quality of life (due to adverse events) should be the main
criteria for a drug selection. In this regard, we believe that HSN431 has
a potential to be translated in the clinic since it could be dosed to mice
for several weeks without any obvious signs of toxicity, such as weight
loss or animal discomfort, and importantly drastically improved survival of mice injected with AML cells (Fig. 5).
In summary, we have developed alkynyl aminoisoquinoline and
alkynyl naphthyridine compounds with potent in vitro FLT3-Src kinase
inhibition. The compounds demonstrated potent activities against TKIresistant FLT3-ITD cell lines and were efﬁcacious in in vivo mouse AML
studies. HSN431 and analogs thereof could be developed further as
anti-AML compounds.
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